tradingkey.logo

Prenetics Global Ltd

PRE

12.000USD

+1.160+10.70%
終値 09/19, 16:00ET15分遅れの株価
154.73M時価総額
損失額直近12ヶ月PER

Prenetics Global Ltd

12.000

+1.160+10.70%
詳細情報 Prenetics Global Ltd 企業名
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
企業情報
企業コードPRE
会社名Prenetics Global Ltd
上場日Jul 06, 2021
最高経営責任者「CEO」Mr. Joel Neoh
従業員数285
証券種類Ordinary Share
決算期末Jul 06
本社所在地Unit 703-706, K11 Atelier King's Road, 728 King's Road, Quarry Bay
都市
証券取引所London Stock Exchange
Hong Kong
郵便番号- -
電話番号85222109588
ウェブサイトhttps://ir.prenetics.com/
企業コードPRE
上場日Jul 06, 2021
最高経営責任者「CEO」Mr. Joel Neoh
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Dr. Chi Hung (Lawrence) Tzang, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Ms. Wing Kwan (Winnie) Chiu
Ms. Wing Kwan (Winnie) Chiu
Independent Director
Independent Director
--
--
Mr. Joel Neoh
Mr. Joel Neoh
Chief Consumer Officer, Chief Executive Officer of CircleDNA
Chief Consumer Officer, Chief Executive Officer of CircleDNA
--
--
Mr. Alan Thomas
Mr. Alan Thomas
Vice President, Supply Chain & Operations
Vice President, Supply Chain & Operations
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Kathryn Henry
Ms. Kathryn Henry
Independent Director
Independent Director
--
--
Mr. Sheng Wu (Danny) Yeung
Mr. Sheng Wu (Danny) Yeung
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Senthil Sundaram, M.D.
Dr. Senthil Sundaram, M.D.
Chief Clinical Officer
Chief Clinical Officer
--
--
Mr. David Vanderveen
Mr. David Vanderveen
Independent Director
Independent Director
--
--
Ms. Jordan Lemerande
Ms. Jordan Lemerande
Vice President - Product Development
Vice President - Product Development
--
--
Mr. Yin Pan (Ben) Cheng
Mr. Yin Pan (Ben) Cheng
Independent Director
Independent Director
--
--
収益内訳
通貨: USD更新時刻: Sun, Jul 6
通貨: USD更新時刻: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
データなし
地域別USD
会社名
収益
比率
Hong Kong
14.27M
46.59%
Taiwan
7.09M
23.16%
The United States
5.51M
18.00%
United Kingdom
2.78M
9.08%
Rest of the world
972.00K
3.17%
事業別
地域別
データなし
株主
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
株主統計
種類
株主統計
株主統計
比率
Dennis (Lo Yuk Ming)
8.41%
Genetel Bioventures Ltd
5.36%
Lawrence (Tzang Chi Hung)
4.69%
Eastspring Investments (Singapore) Limited
3.74%
Aspex Management (HK) Limited
3.02%
他の
74.78%
株主統計
株主統計
比率
Dennis (Lo Yuk Ming)
8.41%
Genetel Bioventures Ltd
5.36%
Lawrence (Tzang Chi Hung)
4.69%
Eastspring Investments (Singapore) Limited
3.74%
Aspex Management (HK) Limited
3.02%
他の
74.78%
種類
株主統計
比率
Individual Investor
14.52%
Corporation
5.36%
Investment Advisor
4.22%
Hedge Fund
3.02%
Research Firm
2.81%
Investment Advisor/Hedge Fund
0.07%
他の
70.00%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
30
3.73M
32.59%
-1.27M
2025Q1
31
3.72M
35.24%
-295.48K
2024Q4
35
3.71M
34.90%
-336.29K
2024Q3
37
3.69M
34.65%
-448.54K
2024Q2
38
3.76M
35.34%
-535.47K
2024Q1
88
5.56M
55.93%
+1.27M
2023Q4
94
4.17M
42.91%
+30.90K
2023Q3
99
4.01M
43.06%
+108.37K
2023Q2
98
3.11M
36.85%
-918.88K
2023Q1
94
3.14M
40.86%
+44.13K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Dennis (Lo Yuk Ming)
962.96K
8.41%
--
--
Apr 24, 2025
Genetel Bioventures Ltd
613.79K
5.36%
--
--
Sep 30, 2024
Lawrence (Tzang Chi Hung)
537.10K
4.69%
--
--
Apr 24, 2025
Eastspring Investments (Singapore) Limited
427.96K
3.74%
--
--
Mar 31, 2025
Aspex Management (HK) Limited
346.15K
3.02%
--
--
Mar 31, 2025
Nomura Securities Co., Ltd.
333.53K
2.91%
+10.58K
+3.27%
Mar 31, 2025
Chun (Lo Hoi)
162.62K
1.42%
--
--
Apr 24, 2025
Morgan Stanley Smith Barney LLC
2.12K
0.02%
--
--
Mar 31, 2025
詳細を見る
関連ETF
更新時刻: Tue, Sep 2
更新時刻: Tue, Sep 2
銘柄名
比率
iShares Micro-Cap ETF
0.02%
iShares Micro-Cap ETF
比率0.02%
配当金
過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
日付
種類
比率
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
Nov 01, 2023
Merger
15→1
KeyAI